Comparison of fecal elastase-1 determination with the secretin-cholecystokinin test in patients with cystic fibrosis

What Was Tested

Researchers studied Secretin and Cholecystokinin (CCK) in this controlled clinical trial publication.

The aim of the study was to evaluate the sensitivity of fecal elastase-1 in relation to the secretin-CCK test and quantitative fecal fat excretion in CF patients.

Why It Was Studied

The secretin-cholecystokinin (CCK) test is the gold standard in the evaluation of exocrine pancreatic insufficiency.

Because of its invasive character, it is of limited value in cystic fibrosis (CF) patients, especially in those with severe respiratory disease.

Who Took Part

The abstract describes 28 patients taking part.

By PubMed's age tags, the people studied were young children, children, teenagers and adults, both men and women.

The study comprised 28 patients (11 females and 17 males) aged 4 to 20 years.

In all patients the secretin-CCK test and determination of fecal elastase-1 concentration (with enzyme-linked immunosorbent assay) and fecal fat excretion were performed.

What Was Measured

The secretin-cholecystokinin (CCK) test is the gold standard in the evaluation of exocrine pancreatic insufficiency.

The subject headings attached to it are Cholecystokinin, Clinical Enzyme Tests, Cystic Fibrosis, Exocrine Pancreatic Insufficiency, Feces, Pancreatic Elastase and Secretin.

What This Means in Plain Language

This is a controlled clinical trial of Secretin and Cholecystokinin (CCK) in 28 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (Scandinavian journal of gastroenterology), a journal based in England.

More context: the Secretin compound page and the Cholecystokinin (CCK) compound page, all human trials.